Ifetroban sodium: An effective TxA2/PGH2 receptor antagonist

Cardiovascular Drug Reviews

Volumn 19, Issue 2, 2001, Pages 97-115

  Rosenfeld, Louis ^a   Grover, Gary J ^b   Stier Jr , Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cyclooxygenase; Hypertension; Ifetroban sodium; Myocardial ischemia; PGH2; Platelet activation; Prostaglandin H2; Stroke; Thomboxane A2; Thrombosis; TxA2; TxA2 PGH2 receptor; Vascular contraction

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DAZOXIBEN; IFETROBAN; INDOMETACIN; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FERRET; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASOCONSTRICTION;

EID: 0034894663     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2001.tb00058.x     Document Type: Review

References (77)

1. Lack of effect of aspirin on myocardial infarct size in the dog
2. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia
3. 2 receptor antagonists after porcine carotid bypass
4. 2 receptors in aortic rings of hypertensive rats
5. Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension: Relationship to nitric oxide
6. Disposition of radiolabeled ifetroban in rats, dogs, monkeys and humans
7. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: Involvement of endothelium generated thromboxane
8. Central thromboxane receptors: mRNA expression and mediation of pressor responses
9. 2 receptor activation in rats
10. Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs
11. Failure of aspirin to interfere with the cardioprotective effects of ifetroban
12. Dose-related cardioprotection by ifetroban in relation to inhibition of ex vivo platelet function
13. 2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve
14. 2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia
15. Thromboxane receptor antagonist BMS- 180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs
16. 2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion
17. Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog
18. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets
19. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides
20. Single dose ifetroban-aspirin interaction in healthy male volunteers
21. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension
22. Preservation of myocardium in transient ischemia by the thromboxane synthetase inhibitor UK 38,485
23. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia
24. Direct injection for high sample throughput capillary gas chromatographic-mass spectrometric bioanalysis
25. 2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta
26. 2 receptor antagonist, in stroke-prone spontaneously hypertensive rats
27. Ifetroban sodium
28. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril
29. Kinetic analysis by HPLC - Electrospray mass spectrometry of the pH-dependent acyl migration and solvolysis as the decomposition pathways of ifetroban 1-O-acyl glucuronide
30. Gastroprotective effect of BMS 180,291: A new thromboxane receptor antagonist
31. 2 receptor blockade improves contractile function following cardiopulmonary bypass in dogs and pigs
32. Thromboxane release during pacing-induced angina pectoris: Possible vasoconstrictor influence on the coronary vasculature
33. 2 receptor antagonist, in healthy male volunteers
34. Clinical benchmark for healing of chronic venous ulcers
35. 2 in responses of cerebral arterioles during chronic hypertension
36. Myocardial ischemia: Platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin
37. 2 receptor antagonists
38. 2antagonists-BMS 180,291: A new clinical candidate
39. Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead
40. Ifetroban sodium
41. 2/prostaglandin endoperoxide receptors in porcine carotid arteries
42. A practical synthesis of ifetroban sodium
43. Diasterooselective reaction of a grignard reagent with chiral imides: A practical preparation of a key intermediate in the synthesis of ifetroban sodium
44. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat
45. 2/prostaglandin endoperoxide (TP) receptor antagonist
46. 2/prostaglandin endoperoxide receptor antagonist
47. 2α receptors and is mediated by thromboxane receptors
48. Isolation and identification of lysophosphatidylcholines as endogenous modulators of thromboxane receptors
49. Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteromic shock
50. Newer antithrombotic drugs
51. 2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides
52. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
53. The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis
54. Superior activity of a thromboxane receptor antagonist compared to aspirin in rat models of arterial and venous thrombosis
55. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis
56. A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin
57. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys
58. Effect of long-acting thromboxane receptor antagonist (BMS-180,291) on experimental antiphosphoslipid-syndrome
59. Venous leg ulcers
60. Endothelium-derived constricting factor in renovascular hypertension
61. 2 mediates augmented polymorphonuclear leukocyte adhesiveness
62. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats
63. 2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats
64. 2 in hypertension
65. Ifetroban
66. A chemoselective, acid mediated conversion of amide acetal to oxazole: The key step in the synthesis of cardiovascular drug, ifetroban sodium
67. 2 receptor antagonist, on platelet function in healthy men
68. Dissociation of endothelial cell dysfunction and blood pressure in SHR
69. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide
70. The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
71. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium
72. In vitro model(s) for the percutaneous delivery of active tissue repair agents
73. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
74. Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets
75. 2 receptors maintain hypertension throughout 2K, 1C Goldblatt hypertension in the rat
76. 2 receptors
77. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells